Literature DB >> 17456768

Emergence of anti-red blood cell antibodies triggers red cell phagocytosis by activated macrophages in a rabbit model of Epstein-Barr virus-associated hemophagocytic syndrome.

Wen-Chuan Hsieh1, Yao Chang, Mei-Chi Hsu, Bau-Shin Lan, Guan-Chung Hsiao, Huai-Chia Chuang, Ih-Jen Su.   

Abstract

Hemophagocytic syndrome (HPS) is a fatal complication frequently associated with viral infections. In childhood HPS, Epstein-Barr virus (EBV) is the major causative agent, and red blood cells (RBCs) are predominantly phagocytosed by macrophages. To investigate the mechanism of RBC phagocytosis triggered by EBV infection, we adopted a rabbit model of EBV-associated HPS previously established by using Herpesvirus papio (HVP). The kinetics of virus-host interaction was studied. Using flow cytometry, we detected the emergence of antibody-coated RBCs, as well as anti-platelet antibodies, at peak virus load period at weeks 3 to 4 after HVP injection, and the titers increased thereafter. The presence of anti-RBCs preceded RBC phagocytosis in tissues and predicted the full-blown development of HPS. The anti-RBC antibodies showed cross-reactivity with Paul-Bunnell heterophile antibodies. Preabsorption of the HVP-infected serum with control RBCs removed the majority of anti-RBC activities and remarkably reduced RBC phagocytosis. The RBC phagocytosis was specifically mediated via an Fc fragment of antibodies in the presence of macrophage activation. Therefore, the emergence of anti-RBC antibodies and the presence of macrophage activation are both essential in the development of HPS. Our observations in this animal model provide a potential mechanism for hemophagocytosis in EBV infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17456768      PMCID: PMC1854957          DOI: 10.2353/ajpath.2007.060772

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  34 in total

1.  Upregulation of tumor necrosis factor-alpha gene by Epstein-Barr virus and activation of macrophages in Epstein-Barr virus-infected T cells in the pathogenesis of hemophagocytic syndrome.

Authors:  J D Lay; C J Tsao; J Y Chen; M E Kadin; I J Su
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

2.  Structure and pathophysiology of the erythrocyte membrane-associated Paul-Bunnell heterophile antibody determinant in Epstein-Barr virus-associated disease.

Authors:  R Patarca; M A Fletcher
Journal:  Crit Rev Oncog       Date:  1995

3.  Histiocytic medullary reticulosis: a lethal form of primary EBV infection in young children in Taiwan.

Authors:  I J Su; H J Hsieh; C Y Lee
Journal:  Lancet       Date:  1989-02-18       Impact factor: 79.321

4.  Virus-associated hemophagocytic syndrome due to Epstein-Barr virus.

Authors:  R P Reisman; M A Greco
Journal:  Hum Pathol       Date:  1984-03       Impact factor: 3.466

5.  Epstein-Barr virus (EBV) infects T lymphocytes in childhood EBV-associated hemophagocytic syndrome in Taiwan.

Authors:  I J Su; R L Chen; D T Lin; K S Lin; C C Chen
Journal:  Am J Pathol       Date:  1994-06       Impact factor: 4.307

6.  Clinicopathological spectrum of haemophagocytic syndrome in Epstein-Barr virus-associated peripheral T-cell lymphoma.

Authors:  M Yao; A L Cheng; I J Su; M T Lin; W C Uen; H F Tien; C H Wang; Y C Chen
Journal:  Br J Haematol       Date:  1994-07       Impact factor: 6.998

7.  Fulminant childhood hemophagocytic syndrome mimicking histiocytic medullary reticulosis. An atypical form of Epstein-Barr virus infection.

Authors:  R L Chen; I J Su; K H Lin; S H Lee; D T Lin; W M Chuu; K S Lin; L M Huang; C Y Lee
Journal:  Am J Clin Pathol       Date:  1991-08       Impact factor: 2.493

8.  Malignant lymphoma in the X-linked lymphoproliferative syndrome.

Authors:  D S Harrington; D D Weisenburger; D T Purtilo
Journal:  Cancer       Date:  1987-04-15       Impact factor: 6.860

Review 9.  Hemophagocytic syndrome in Epstein-Barr virus-associated T-lymphoproliferative disorders: disease spectrum, pathogenesis, and management.

Authors:  I J Su; C H Wang; A L Cheng; R L Chen
Journal:  Leuk Lymphoma       Date:  1995-11

Review 10.  Familial hemophagocytic lymphohistiocytosis.

Authors:  G E Janka
Journal:  Eur J Pediatr       Date:  1983 Jun-Jul       Impact factor: 3.183

View more
  7 in total

1.  Up-regulation of activating transcription factor-5 suppresses SAP expression to activate T cells in hemophagocytic syndrome associated with Epstein-Barr virus infection and immune disorders.

Authors:  Huai-Chia Chuang; Ju-Ming Wang; Wen-Chuan Hsieh; Yao Chang; Ih-Jen Su
Journal:  Am J Pathol       Date:  2008-10-02       Impact factor: 4.307

Review 2.  Co-opting biology to deliver drugs.

Authors:  Parisa Yousefpour; Ashutosh Chilkoti
Journal:  Biotechnol Bioeng       Date:  2014-07-21       Impact factor: 4.530

3.  Hemophagocytic Lymphohistiocytosis Induced by Severe Pandemic Influenza A (H1N1) 2009 Virus Infection: A Case Report.

Authors:  Xiang-Yan Zhang; Xian-Wei Ye; Duan-Xing Feng; Jing Han; Dan Li; Cheng Zhang
Journal:  Case Rep Med       Date:  2011-04-14

4.  Deciphering the role of Epstein-Barr virus in the pathogenesis of T and NK cell lymphoproliferations.

Authors:  Christopher P Fox; Claire Shannon-Lowe; Martin Rowe
Journal:  Herpesviridae       Date:  2011-09-07

5.  Plasma cells increased markedly in lymph node in hemophagocytic syndrome: a case report.

Authors:  Li Congyang; Hu Xuexin; Li Hao; Li Chunge; Miao Yingye
Journal:  Cases J       Date:  2009-11-27

6.  MUC16/CA125 in the context of modular proteins with an annotated role in adhesion-related processes: in silico analysis.

Authors:  Miroslava Jankovic; Ninoslav Mitic
Journal:  Int J Mol Sci       Date:  2012-08-21       Impact factor: 6.208

7.  Successful treatment of refractory hyperferritinemic syndromes with canakinumab: a report of two cases.

Authors:  Riccardo Papa; Valentina Natoli; Roberta Caorsi; Francesca Minoia; Marco Gattorno; Angelo Ravelli
Journal:  Pediatr Rheumatol Online J       Date:  2020-07-11       Impact factor: 3.054

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.